Children with ADHD and taking Drugs found at 100% Increased Risk of Obesity as Adults

Obesity in Men With Childhood ADHD: A 33-Year Controlled, Prospective, Follow-up Study

A new study conducted by researchers at the Child Study Center at NYU Langone Medical Center found men diagnosed as children with attention-deficit/hyperactivity disorder (ADHD) were twice as likely to be obese in a 33-year follow-up study compared to men who were not diagnosed with the condition ; the Body Mass Index of children diagnosed with ADHD and put on medications to treat the condition can increase months or even years after they’ve stopped taking their treatment.


image of American Academy of Pediatrics logo
A new study found men diagnosed as children with #ADHD were twice as likely to be obese in a 33-year follow-up study compared to men who were not diagnosed with the condition.

To compare BMI and obesity rates in fully grown men with and without childhood attention-deficit/hyperactivity disorder (ADHD). We predicted higher BMI and obesity rates in: (1) men with, versus men without, childhood ADHD; (2) men with persistent, versus men with remitted, ADHD; and (3) men with persistent or remitted ADHD versus those without childhood ADHD.

Men with childhood ADHD were from a cohort of 207 white boys (referred at a mean age of 8.3 years), interviewed blindly at mean ages 18 (FU18), 25 (FU25), and 41 years (FU41). At FU18, 178 boys without ADHD were recruited. At FU41, 111 men with childhood ADHD and 111 men without childhood ADHD self-reported their weight and height.

Men with childhood ADHD had significantly higher BMI (30.1 ± 6.3 vs 27.6 ± 3.9; P = .001) and obesity rates (41.4% vs 21.6%; P = .001) than men without childhood ADHD. Group differences remained significant after adjustment for socioeconomic status and lifetime mental disorders. Men with persistent (n = 24) and remitted (n = 87) ADHD did not differ significantly in BMI or obesity rates. Even after adjustment, men with remitted (but not persistent) ADHD had significantly higher BMI (B: 2.86 [95% CI: 1.22 to 4.50]) and obesity rates (odds ratio: 2.99 [95% CI: 1.55 to 5.77]) than those without childhood ADHD.

Children with ADHD are at increased risk of obesity as adults. Findings of elevated BMI and obesity rates in men with remitted ADHD require replication.

Sources and Press releases
  • Obesity in Men With Childhood ADHD: A 33-Year Controlled, Prospective, Follow-up Study, PEDIATRICS Vol. 131 No. 6 June 1, 2013, pp. e1731 -e1738, (doi: 10.1542/peds.2012-0540) /131/6/e1731
  • First Long-Term Study Reveals Link Between Childhood ADHD and Obesity, The Office of Communications & Public Affairs, May 20, 2013, News Releases

Women and the Crisis in Sex Hormones

Complete handbook by Barbara Seaman, published in 1981, about birth control, DES, menopause, remedies and more…

Women and the Crisis in Sex Hormones book cover image
Complete handbook published in 1981 about birth control, DES, menopause, remedies and more…

Barbara Seaman, author of The Greatest Experiment Ever Performed on Women, previously wrote a book entitled The Doctor’s Case Against the Pill, which was almost single-handedly responsible for calling the attention of Senator Nelson and his committee on drugs, as well as that of the public, to the dangers of hormone contraceptives for women, as well as to the indifference and perhaps denial of the medical profession generally. Now, in the Women and the Crisis in Sex Hormones book coauthored by her husband, a psychiatrist and psychopharmacologist, the subject is extended to a comprehensive examination of the entire contraceptive field.

Written with a biting and sardonic humor at times, it is a remarkable piece of investigative reporting, comprehensive enough to serve as a reliable reference work. It considers alternatives to hormonal contraception, including the diaphragm, cervical cap, intrauterine device, foam, current rhythm methods, sterilization, abortion, the condom, vasectomy, and a pill for men. It considers menopause and the use of hormones in relation to it.

Sources JAMA 1978;239(20):2179. doi:10.1001/jama.1978.03280470091039

The first chapters of this book are about DES history.

More DES DiEthylStilbestrol Resources
On Flickr®

Potential Health effects of Toxic Chemicals in Feminine Care Products

Products intended for use on or in an incredibly absorbent part of a woman’s body are marketed and sold with little to no data assuring the ingredients they contain are safe

image of Chem Fatale Report cover page
The Women’s Voices for the Earth November 2013 Chem Fatale report found toxic chemicals commonly used in feminine care products like pads and tampons.

Feminine care. Feminine hygiene. Personal cleansing products. Intimate care. No matter what you call them, these consumer products are manufactured for and marketed exclusively to women. The purpose of feminine care products is to clean, moisturize, absorb discharge or otherwise treat the sensitive skin and tissues of the vaginal area. Women are told they are necessary for personal hygiene, a “fresher feeling,” or “greater confidence,” and the companies marketing these products imply that this improved cleanliness will promote good health and increase sex appeal.

A closer look at the impacts of these products, and the chemicals they contain, tell a much different story. Products intended for use on or in an incredibly absorbent part of a woman’s body are marketed and sold with little to no data assuring the ingredients they contain are safe. Ingredients are determined “safe,” operating under the premise that they are used on ordinary skin just like other cosmetic products. That means chemicals of concern such as carcinogens, reproductive toxins, endocrine disruptors, and allergens are being used on, or even in, the extremely permeable mucus membranes of the vaginal area. ”

  • Introduction
    • what are feminine care Products?
    • feminine care Products: what makes them special?
    • who uses feminine care?
  • How feminine care Products are regulated
  • Potential HealtH Hazards associated with chemicals found in feminine care Products
    • secret toxic chemicals in fragrance
    • tampons
    • menstrual pads
    • feminine wipes
    • feminine wash
    • douche
    • feminine deodorant
    • over-the-counter anti-itch creams
  • Solutions
    • Personal alternatives
    • recommended federal and corporate Policy changes
  • Appendix : chemicals of concern in feminine care Products

Read the Women’s Voices for the Earth
November 2013 Chem Fatale report

Discover Women’s Voices Earth blogFacebook and Twitter.

Diethylstilbestrol Contraindicated in Pregnancy

Selected Item from the FDA Drug Bulletin 1971

image of the FDA-building
The FDA did NOT ban DES, but issued a warning and urged doctors to stop prescribing it for their pregnant patients.

Considering the risks and the numerous studies showing DiEthylStilbestrol inefficiency and harm, it is unbelievable that the FDA never banned the use of DES during pregnancy.

Many articles about DiEthylStilbestrol (DES) mention that the Food and Drug Administration (FDA) banned DES for pregnant women in 1971.
The FDA did NOT ban DES, but issued a warning and urged doctors to stop prescribing it for their pregnant patients. Most doctors did, but not all, and the information regarding the contraindication took many years to reach France and other European countries where the drug continued to be prescribed to pregnant women. Since 1971,  many studies have shown a variety of health effects associated with DES exposure, adenocarcinoma but also breast cancer and infertility to name just a few.  In 2011, 40 years after the DES cancer link was made, the FDA acknowledged the DES tragedy but refused to apologize to the many victims of this drug scandal. To this day, not one drug company has ever apologized or accepted responsibility for the DES tragedy. Below is the initial warning issued by the FDA. Considering the risks and the numerous studies showing its inefficiency and harm, it is unbelievable that the FDA never banned the use of DES during pregnancy.

Diethylstilbestrol Contraindicated in Pregnancy: Drug’s Use Linked to Adenocarcinoma in the Offspring

image of the fda logo
Selected Item from the FDA Drug Bulletin – November 1971: Diethylstilbestrol Contraindicated in Pregnancy

WE WISH TO BRING to the attention of all physicians, hospitals, and medical personnel an important possible toxic effect of diethylstilbestrol (DES) reported for the first time in April 1971 by Herbst et al.

From their studies the authors concluded that maternal ingestion of diethylstilbestrol during pregnancy appears to increase the risk of vaginal adenocarcinoma developing years later in the offspring exposed. The authors studied eight cases of adenocarcinoma of the vagina in patients born between 1946 and 1951. The malignancies were identified and treated between 1966 and 1969. In seven of the eight cases, there was a history -of maternal use of diethylstilbestrol. Because this type of malignancy in young girls had rarely been reported previously, the authors conducted a retrospective investigation in an attempt to find factors that may be associated with such malignancy in this age group. Four matched controls were established for each patient and the data obtained were subjected to statistical analysis. A statistically significant relationship was observed for three variables: diethylstilbestrol given during pregnancy (p=.00001), bleeding in that pregnancy (p=less than .05) and prior pregnancy loss (p=less than .01). It is obvious that the most significant of the variables is the administration of diethylstilbestrol during pregnancy.

Since publication of this study, five additional cases of this malignancy associated with the maternal use of diethylstilbestrol have been reported by Greenwald et al. Dr. Herbst, in a recent communication to FDA, has reported an additional 15 cases associated with use of this drug, bringing the total number of known cases to 27. It must be emphasized that this type of epidemiologic study defines only an association and not necessarily a cause-and-effect relationship. Further studies are underway to clarify the significance of these findings.

In the meantime, the FDA is initiating the following precautionary actions:

  1. All manufacturers of DES or closely related congeners (dienestrol, hexestrol, benzestrol, promethestrol) are being notified that appropriate changes will be required in the labeling for such drugs. This change will consist in the listing of pregnancy as a contraindication to the use of diethylstilbestrol and the other above-mentioned compounds.
  2. All other estrogens will be required to have the following WARNING in their labeling: “A statistically significant association has been reported between maternal ingestion during pregnancy of diethylstilbestrol and the occurrence of vaginal carcinoma developingyears later in the offspring. Whether such an association is applicable to all estrogens is not known at this time. In any event, estrogens are not indicated for use during pregnancy.”
  3. Epidemiological studies are being initiated to determine the true incidence of this disease in young women, the number at risk, the characteristics of patient populations with this malignancy, and the probability of a cause-and-effect relationship.

Both FDA and the medical profession face a responsibility to help determine whether this reported association constitutes a cause-and-effect relationship. We ask that all physicians consider appropriate steps to assist FDA casefinding and to protect any patients who might be at risk.

It may be possible to trace the offspring of those mothers who received DES during pregnancy. All physicians should be especially’ alert for young women whose mothers may have received hormonal therapy during pregnancy, particularly those young women who may be experiencing irregular vaginal bleeding. The association should be a routine consideration for physicians whose practice includes young women.

This is a previously unsuspected health problem. Further information is essential to the FDA and to the medical profession. We ask your help in reporting any cases you encounter for entry in a case registry. FDA will take every possible step to insure that you are kept abreast of new information as soon as it can be gathered and analyzed. For your convenience, an adverse reaction reporting form is printed below. FDA will forward a supply of forms to each practicing physician as soon as they are printed. Facsimile forms are acceptable.


Selected Item from the FDA Drug Bulletin—November 1971: Diethylstilbestrol Contraindicated in Pregnancy, Calif Med. Feb 1972; 116(2): 85–86. v.116(2); PMC1518220 – Download the full PDF.

More DES DiEthylStilbestrol Resources

Air Pollution and Autism: more Evidence that Environmental Toxins play a Role in ASD

Growing evidence that ASD is linked to pollution, with babies 283% more likely to suffer from the condition compared to other birth defects…

Environmental and State-Level Regulatory Factors Affect the Incidence of Autism and Intellectual Disability

A PLOS Computational Biology Journal article offers strong evidence that environmental toxins play a role in the autism spectrum disorder. The research looked at birth defects associated with parental exposure to pollution and found a 1% increase in the defects corresponded to a 283% increase in autism.

image of PLOS Computational Biology logo
An open-access, peer-reviewed journal. @PLOSCompBiol tweets for the PLOS Computational Biology team.

Many factors affect the risks for neurodevelopmental maladies such as autism spectrum disorders (ASD) and intellectual disability (ID). To compare environmental, phenotypic, socioeconomic and state-policy factors in a unified geospatial framework, we analyzed the spatial incidence patterns of ASD and ID using an insurance claims dataset covering nearly one third of the US population. Following epidemiologic evidence, we used the rate of congenital malformations of the reproductive system as a surrogate for environmental exposure of parents to unmeasured developmental risk factors, including toxins. Adjusted for gender, ethnic, socioeconomic, and geopolitical factors, the ASD incidence rates were strongly linked to population-normalized rates of congenital malformations of the reproductive system in males (an increase in ASD incidence by 283% for every percent increase in incidence of malformations, 95% CI: [91%, 576%], p<6×10−5). Such congenital malformations were barely significant for ID (94% increase, 95% CI: [1%, 250%], p = 0.0384). Other congenital malformations in males (excluding those affecting the reproductive system) appeared to significantly affect both phenotypes: 31.8% ASD rate increase (CI: [12%, 52%], p<6×10−5), and 43% ID rate increase (CI: [23%, 67%], p<6×10−5). Furthermore, the state-mandated rigor of diagnosis of ASD by a pediatrician or clinician for consideration in the special education system was predictive of a considerable decrease in ASD and ID incidence rates (98.6%, CI: [28%, 99.99%], p = 0.02475 and 99% CI: [68%, 99.99%], p = 0.00637 respectively). Thus, the observed spatial variability of both ID and ASD rates is associated with environmental and state-level regulatory factors; the magnitude of influence of compound environmental predictors was approximately three times greater than that of state-level incentives. The estimated county-level random effects exhibited marked spatial clustering, strongly indicating existence of as yet unidentified localized factors driving apparent disease incidence. Finally, we found that the rates of ASD and ID at the county level were weakly but significantly correlated (Pearson product-moment correlation 0.0589, p = 0.00101), while for females the correlation was much stronger (0.197, p<2.26×10−16).

Sources and Press releases

Older Related Articles

Air Pollution and Newly Diagnostic Autism Spectrum Disorders: A Population-Based Cohort Study in Taiwan


There is limited evidence that long-term exposure to ambient air pollution increases the risk of childhood autism spectrum disorder (ASD). The objective of the study was to investigate the associations between long-term exposure to air pollution and newly diagnostic ASD in Taiwan. We conducted a population-based cohort of 49,073 children age less than 3 years in 2000 that were retrieved from Taiwan National Insurance Research Database and followed up from 2000 through 2010. Inverse distance weighting method was used to form exposure parameter for ozone (O3), carbon monoxide (CO), nitrogen dioxide (NO2), sulfur dioxide (SO2), and particles with aerodynamic diameter less than 10 µm (PM10). Time-dependent Cox proportional hazards (PH) model was performed to evaluate the relationship between yearly average exposure air pollutants of preceding years and newly diagnostic ASD. The risk of newly diagnostic ASD increased according to increasing O3, CO, NO2, and SO2 levels. The effect estimate indicating an approximately 59% risk increase per 10 ppb increase in O3 level (95% CI 1.42–1.79), 37% risk increase per 10 ppb in CO (95% CI 1.31–1.44), 340% risk increase per 10 ppb increase in NO2 level (95% CI 3.31–5.85), and 17% risk increase per 1 ppb in SO2 level (95% CI 1.09–1.27) was stable with different combinations of air pollutants in the multi-pollutant models. Our results provide evident that children exposure to O3, CO, NO2, and SO2 in the preceding 1 year to 4 years may increase the risk of ASD diagnosis.

Sources PLOSone September 25, 2013DOI: 10.1371/journal.pone.0075510

Autism Spectrum Disorders in Relation to Distribution of Hazardous Air Pollutants in the San Francisco Bay Area


To explore possible associations between autism spectrum disorders (ASD) and environmental exposures, we linked the California autism surveillance system to estimated hazardous air pollutant (HAP) concentrations compiled by the U.S. Environmental Protection Agency.

Subjects included 284 children with ASD and 657 controls, born in 1994 in the San Francisco Bay area. We assigned exposure level by census tract of birth residence for 19 chemicals we identified as potential neurotoxicants, developmental toxicants, and/or endocrine disruptors from the 1996 HAPs database. Because concentrations of many of these were highly correlated, we combined the chemicals into mechanistic and structural groups, calculating summary index scores. We calculated ASD risk in the upper quartiles of these group scores or individual chemical concentrations compared with below the median, adjusting for demographic factors.

The adjusted odds ratios (AORs) were elevated by 50% in the top quartile of chlorinated solvents and heavy metals [95% confidence intervals (CIs), 1.1–2.1], but not for aromatic solvents. Adjusting for these three groups simultaneously led to decreased risks for the solvents and increased risk for metals (AORs for metals: fourth quartile = 1.7; 95% CI, 1.0–3.0; third quartile = 1.95; 95% CI, 1.2–3.1). The individual compounds that contributed most to these associations included mercury, cadmium, nickel, trichloroethylene, and vinyl chloride.

Our results suggest a potential association between autism and estimated metal concentrations, and possibly solvents, in ambient air around the birth residence, requiring confirmation and more refined exposure assessment in future studies.

Sources NCBI Environ Health Perspect. Sep 2006; 114(9): 1438–1444 PMC1570060

Are BPA-free Plastic Containers really Safe?

What is the BPS compound?

Registered dietitian Nancy Dell reviews bisphenol-A (BPA), BPA-free, BPS and plastic packaging.

More information

How could a seemingly Healthy Boy grow up with the Feelings of a Little Girl?

Did something just happen last week or was it at a young age? Was it a curse from God or a side effect from modern medicine?

little angel image
Laura Amato’s mother was immediately placed on DES when she became pregnant again.

So, how could this all happen? How could a seemingly healthy boy grow up with the feelings of a little girl? Did something just happen last week or was it at a young age? Was it from abuse and cruelty or from circumstances that just happened? Was it a curse from God or a side effect from modern medicine? Can This be prevented from happening to some other boy? Hopefully this Biography can answer some of your questions and maybe some of mine as well.

Before my mother had her first child she suffered three miscarriages. Modern medicine at that time was just starting to study hormonal effects in childbirth. It was discovered that my mother’s hormone levels were deficient in Estrogen after conception. Scientists introduced a new drug called DES which was designed to improve these levels. So when my mother became pregnant with me she was immediately placed on DES… ”

Continue reading Laura Amato Transsexual Biography, Parts 1 and 2, Laura’

More information

Secret Toxic Chemicals in Pads

Toxic chemicals do not belong in feminine products.
Tell Tampax to Detox the Box!

Toxic chemicals don’t belong in Pads. Period.

toxic chemicals in pads infographics
Toxic chemicals don’t belong in Pads. Period.

Always: Detox the Box!

Women’s Voices for the Earth November 2013 Chem Fatale report found toxic chemicals commonly used in feminine care products like pads and tampons. ” Unfortunately, because pads and tampons are regulated as “medical devices” and not “personal care products,” companies aren’t required by law to disclose any of the ingredients used in these products. We know that Procter & Gamble, makers of Tampax and Always, uses some toxic fragrance chemicals – and we have a right to know what else they’re using in pads and tampons. ”

Sources and More Information

On Flickr®

Play to Cure : Genes in Space

How the cancer ™ game got there…

In a world first collaboration lead by Cancer Research UK, Amazon Web Services, Facebook and Google developers joined academics, scientists, gamers and designers for a weekend GameJam. Their aim was to transform Cancer Research UK’s cancer gene data into an engaging and playable game that would generate robust scientific analysis. In just 48 sleep deprived hours, this inspirational collaboration produced 12 gaming prototypes based on Cancer Research UK’s cancer gene data – truly epic achievement.

  • Video by Cancer Research UK published on 25 Jul 2013.
  • Play to Cure™ Genes in Space is a pioneering mobile phone game from Cancer Research UK, which lets players unravel real cancer data through a space game. What would have taken scientists hours to analyse, can now be done faster with your help and the collective force of thousands of players. Watch this to find out more about the game and see real game play.
  • Download at the Apple App Store or Google Play.
More information

FDA Panel recommends Roche HPV Test as Primary Tool for Cervical Cancer Screening

Can Roche’s DNA Test Replace Pap Smear?

image of roche hpv test
The Roche cobas® HPV Test is seen as better primary tool for cervical cancer screening.

The Food and Drug Administration‘s Medical Devices Advisory Committee Microbiology Panel agreed by a vote of 13-0 that a HPV test developed by Roche should be approved by the FDA as a primary tool for cervical cancer screening.

Currently, women are tested for human papillomavirus (HPV) during a Pap test – examining a cervical sample under the microscope looking for abnormalities. – or after a Pap smear shows abnormal changes on their cervix. The new cobas® HPV test from Roche detects the DNA of human papillomavirus which causes almost all cases of cervical cancer.

Sources and More Information